Merck KGaA in talks to sell its biosimilars R&D ops as shakeout looms
The biosimilars business is just getting established, but the shakeout among a group of high-powered rivals is already taking shape.
Merck KGaA CEO Stefan Oschmann …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.